Retatrutide vs Tirzepatide vs Semaglutide: What the 2024–2025 Research Actually Shows

Three compounds. Three different receptor profiles. And a research community that still can't agree on which one tells the more interesting story.

I want to cut through the noise here — not with marketing language, but with what the actual trial data from the past 18 months shows, and why the differences matter for how researchers are designing their protocols.

First, the receptor story — because it explains everything downstream

This is where most comparisons go wrong. They jump straight to weight loss percentages without explaining why the numbers differ. So let's start here.

Semaglutide is a GLP-1 receptor agonist. One target. It slows gastric emptying, suppresses appetite via hypothalamic signaling, and improves insulin secretion in a glucose-dependent manner. Clean mechanism. Well-characterized. The SUSTAIN and STEP trial data goes back years.

Tirzepatide adds GIP receptor agonism. That second receptor does something interesting — GIP appears to enhance the GLP-1 effect in adipose tissue specifically, which is part of why the body composition data looks different from semaglutide even at comparable weight loss. The SURMOUNT trials showed this clearly.

Retatrutide goes further. GLP-1 + GIP + glucagon receptor agonism. That glucagon component is the variable that makes retatrutide mechanistically distinct. Glucagon drives hepatic glucose output and increases energy expenditure — which is why the Phase 2 data showed metabolic effects that neither of the other two produced at equivalent doses.

Three different tools. Not three versions of the same tool.

What the 2024–2025 data actually shows

Semaglutide — the established baseline

The STEP trials remain the reference point. 2.4mg weekly subcutaneous dosing showed ~15% mean body weight reduction over 68 weeks in the landmark trial. The 2024 SELECT cardiovascular outcomes data added something important: a 20% reduction in major adverse cardiovascular events in adults with obesity and established CVD, independent of weight loss magnitude.

That cardiovascular signal is significant. It suggests GLP-1 receptor agonism has effects beyond metabolic parameters — and it's driving a lot of the current research interest in the class as a whole.

What semaglutide doesn't do well: the weight loss plateau is real, and the lean mass loss data is a consistent finding across trials. Roughly 25-40% of weight lost is lean mass, depending on the population. That's a research question that hasn't been fully resolved.

Tirzepatide — where the body composition story gets interesting

SURMOUNT-1 showed 20.9% mean weight reduction at the highest dose (15mg weekly) over 72 weeks. That's a meaningful step up from semaglutide's numbers in head-to-head context.

But the more interesting finding from 2024 wasn't the weight number — it was the body composition data. The dual GIP/GLP-1 mechanism appears to preferentially drive fat mass reduction with relatively better lean mass preservation compared to GLP-1 monotherapy. The mechanism isn't fully characterized, but the GIP receptor's role in adipocyte differentiation and lipid metabolism is the leading hypothesis.

The SURPASS-CVOT data is still maturing, but early signals on cardiovascular endpoints look consistent with the GLP-1 class effect.

For researchers studying metabolic syndrome, insulin resistance, or body composition specifically — tirzepatide's dual mechanism gives you a different set of variables to work with than semaglutide.

Retatrutide — the 2024 Phase 2 data and what it means

This is where it gets genuinely interesting.

The Phase 2 trial published in NEJM in 2023 (with follow-up analysis through 2024) showed 24.2% mean weight reduction at 48 weeks at the highest dose. That's the headline number. But the mechanism story is more compelling than the percentage.

The glucagon receptor component drives hepatic effects that neither semaglutide nor tirzepatide produce at comparable magnitude — specifically around hepatic lipid metabolism and energy expenditure. In the Phase 2 data, retatrutide showed reductions in liver fat content that were substantially larger than what's been seen with the other two compounds.

For researchers studying NAFLD/NASH pathways, hepatic metabolism, or energy expenditure mechanisms specifically — retatrutide is operating in territory the other two don't fully reach.

The caveat: Phase 2 data. Smaller populations, shorter duration, no cardiovascular outcomes data yet. The Phase 3 program is ongoing. Researchers working with retatrutide are working with a less mature evidence base than the other two — which is both a limitation and, depending on your research question, exactly the point.

Side-by-side: what the data actually shows

The question researchers are actually asking in 2025

It's not "which one is best." That's the wrong frame.

The question is: what is your research endpoint, and which receptor profile gives you the most relevant mechanistic signal for that endpoint?

Studying appetite regulation and hypothalamic signaling? Semaglutide's clean GLP-1 profile gives you the most interpretable data.

Studying body composition, adipose tissue biology, or insulin sensitivity with a body composition component? Tirzepatide's dual mechanism is the more interesting tool.

Studying hepatic metabolism, energy expenditure, or trying to understand what the glucagon receptor contributes to metabolic outcomes? Retatrutide is the only compound in this class that lets you ask that question directly.

That's the actual state of the research in mid-2025. Not a ranking. A set of tools with different mechanistic profiles for different research questions.

A note on sourcing for research

For any of these compounds to produce interpretable data, purity and documentation aren't optional. HPLC verification at ≥99% and endotoxin screening are the baseline. Certificate of Analysis from an ISO-certified manufacturer should accompany every vial.

Star Valley Peptides carries research-grade Semaglutide, Tirzepatide, and Retatrutide — all HPLC-verified, endotoxin-screened, with CoA included.

All compounds are strictly for laboratory and scientific research purposes only. Not intended for human or animal therapeutic use. Not approved by any regulatory authority for clinical application.